Morphine: important safety information updated to highlight availability of different strengths of oral solution. Drugs that cause thromboembolism: pharmacodynamic effects drug group deleted from Appendix 1 interactions. The British National Formulary is divided into various sections; with the main sections on drugs and preparations being organised by body system. BNF - NHS Evidence - Search Engine for Evidence in Health and Social Care". Archived from the original on 1 October 2012 . Retrieved 2012-06-14.

Vaccines update: restructure of Typhoid vaccine monograph—creation of monographs for typhoid vaccine (live) and typhoid vaccine (inactivated). Elias-Jones, A.; Rylance, G. (2005). "The launch of the British National Formulary for Children". Archives of Disease in Childhood. 90 (10): 997–998. doi: 10.1136/adc.2005.080366. PMC 1720111. PMID 16177154. Valproate: re-analysis of study on risks in children of men taking valproate [MHRA/CHM advice] (advice in sodium valproate, valproic acid; see example in sodium valproate). a b c d e "BNF Publications - Books". www.bnf.org. BMJ Group and Royal Pharmaceutical Society. Archived from the original on 17 August 2016 . Retrieved 16 August 2016.British National Formulary for Children - editorial staff". BNFC. NICE . Retrieved 21 January 2021. Hyoscine hydrobromide patches (Scopoderm® 1.5 mg patch or Scopoderm® TTS patch): risk of anticholinergic side effects, including hyperthermia [MHRA/CHM advice]. Information on drugs is drawn from the manufacturers' product literature, medical and pharmaceutical literature, regulatory authorities and professional bodies. Advice is constructed from clinical literature, and reflects, as far as possible, an evaluation of the evidence from diverse sources. The BNF also takes account of authoritative national guidelines and emerging safety concerns. In addition, the Joint Formulary Committee takes advice on all therapeutic areas from advisers from expert groups; this ensures that the BNF's recommendations are relevant to practice. In September 2016, the National Institute for Health and Care Excellence (NICE) in the UK gave NICE accreditation to the processes to produce BNF publications; a further review in 2021 resulted in the successful renewal of accreditation. [3] History [ edit ] BNF for Children BNFC 2019-2020" (PDF). Archived from the original (PDF) on 11 October 2021 . Retrieved 1 May 2022. A new edition of the BNF book is published twice-yearly, in March and September. [1] The current edition is 85, which was published in March 2023. It is a tradition that the colour of each new edition is radically different from the previous. [2] Availability [ edit ]

Aminoglycosides: pre-treatment screening advice on genetic testing for aminoglycoside exposure posing risk to hearing (advice in relevant monographs; see example in gentamicin).

Adrenaline/epinephrine: recall of Emerade® 500 micrograms and Emerade® 300 micrograms auto-injectors, due to the potential for device failure [National Patient Safety Alert advice].

Direct-acting oral anticoagulants (DOACs): paediatric formulations [MHRA/CHM advice] (advice in rivaroxaban). Many individuals and organisations contribute towards the preparation of the BNF. It is authored by Pharmaceutical Press, the Royal Pharmaceutical Society's (RPS) knowledge business; and is jointly published by the BMJ (owned by the BMA), and Pharmaceutical Press (owned by the RPS). It is published under the authority of a Joint Formulary Committee (JFC), [2] which comprises pharmacy, medical, nursing, and lay representatives; there are also representatives from the Medicines and Healthcare products Regulatory Agency (MHRA), the UK Health Departments, and a national guideline producer. Council awards honorary membership to past chairman of the Joint Formulary Committee". The Pharmaceutical Journal. 283: 429. 2009 . Retrieved 20 January 2021. Cefixime [update to include dosing in children from 12 years old for uncomplicated gonorrhoea and disseminated gonococcal infection]. VNRAS.com, BNF 73. "BNF 73" (PDF). Archived (PDF) from the original on 21 October 2021. {{ cite web}}: CS1 maint: numeric names: authors list ( link)Wade, O. L. (1993). "British National Formulary: Its birth, death, and rebirth". BMJ (Clinical Research Ed.). 306 (6884): 1051–1054. doi: 10.1136/bmj.306.6884.1051. PMC 1676980. PMID 8490505. Ceftriaxone [update to include dosing in children from 12 years old for gonococcal conjunctivitis, gonococcal epididymo-orchitis, and disseminated gonococcal infection]. Kendall, MJ (2009). "Chairman of the Joint Formulary Committee, British National Formulary". Clinical Medicine. 9 (4): 349–352. doi: 10.7861/clinmedicine.9-4-349. PMC 4952503. PMID 19728509.